Welcome to our dedicated page for Solventum Corporation news (Ticker: SOLV), a resource for investors and traders seeking the latest updates and insights on Solventum Corporation stock.
Solventum Corporation (SOLV) delivers healthcare innovations through material science and digital solutions across MedSurg, Dental, Health IT, and filtration markets. This news hub provides investors and professionals with essential updates on SOLV's strategic developments and operational milestones.
Track official press releases, earnings reports, and regulatory filings in one centralized location. Our curated collection includes updates on wound care advancements, dental technology launches, health information systems, and filtration solutions, offering insights into SOLV's market leadership.
Discover timely information about product innovations like the V.A.C. wound care systems and AI-driven health IT platforms. The page serves healthcare stakeholders needing reliable updates on SOLV's initiatives in surgical solutions, dental attachments, and purification technologies.
Bookmark this resource for streamlined access to SOLV's corporate announcements. Verify facts directly from primary materials while staying informed about this healthcare innovator's progress in transforming patient care through science-driven solutions.
Thermo Fisher Scientific (NYSE: TMO) has announced a definitive agreement to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. The Solventum business, which generated approximately $1 billion of revenue in 2024, is a leading provider of purification and filtration technologies used in biologics production and other applications.
This acquisition is highly complementary to Thermo Fisher's bioproduction business, expanding its capabilities in biologics development and manufacturing. The transaction is expected to be completed by the end of 2025, subject to regulatory approvals. Once closed, Solventum's business will become part of Thermo Fisher's Life Sciences Solutions segment.
The acquisition is expected to generate mid- to high-single digit organic growth and will be dilutive to adjusted EPS by $0.06 in the first year, but accretive by $0.28 excluding financing costs. Thermo Fisher expects to realize approximately $125 million of adjusted operating income from synergies by year five.
Solventum (NYSE: SOLV) announced that its AI-powered radiology speech reporting solution, Fluency for Imaging, has been ranked #1 in the 2025 Best in KLAS Awards for the fifth time. The solution helps radiologists improve efficiency and reduce burnout by streamlining the reporting process through faster, more accurate documentation.
Dr. Charles Q. Li from Allegheny Health Network praised the system's exceptional voice recognition accuracy and reliability, noting its decade-long use at their facility. The KLAS recognition is based on customer feedback collected through confidential interviews and product evaluations over a one-year period, evaluating solutions across six key pillars: value, product, loyalty, relationship, operations, and culture.
Solventum (NYSE: SOLV) has announced it will release its fourth quarter and full year fiscal 2024 financial results on Thursday, February 27, 2025, after U.S. financial markets close. Following the results announcement, the company's management will host a webcast to discuss the quarterly performance and provide guidance for fiscal year 2025. Additionally, Solventum plans to host an Investor Day in March 2025.
The T1D Fund, an impact investment fund focused on type 1 diabetes solutions, has appointed Elizabeth Mily as CEO. Mily brings over 30 years of experience from roles at Bristol Myers Squibb, Goldman Sachs, and Barclays, where she specialized in corporate strategy and business development.
In her new role, Mily will guide the fund's resource deployment and expand strategic partnerships to build an ecosystem for new therapies. She will serve as the fund's lead public ambassador, working to increase awareness and investment in T1D research and innovation.
Prior to joining T1D Fund, Mily served as Executive Vice President of Strategy & Business Development at Bristol Myers Squibb, overseeing company strategy, external innovation, and business development. She currently serves on the Board of Solventum (NYSE: SOLV) and Ampersand Biomedicines.
Solventum (NYSE: SOLV) has announced its participation in the upcoming Piper Sandler 36th Annual Healthcare Conference. Company executives will engage in a fireside chat scheduled for Wednesday, December 4, 2024, at 11:30 a.m. ET in New York, NY. Interested parties can access both live and archived versions of the discussion through the company's investor relations website at investors.solventum.com.
Solventum (NYSE: SOLV) has launched 3M™ Clarity™ Precision Grip Attachments, a revolutionary 3D-printed innovation for aligner treatment. These attachments are designed to solve major challenges in aligner treatment by providing durable, accurately shaped, and stain-resistant components. The product eliminates technique-sensitive processes and variability risks in treatment, offering precise positioning and customization to each patient's tooth anatomy. The attachments are manufactured using 3D printing technology, combining inorganic filler and organic resin with post-processing techniques for enhanced durability and stain resistance. The product is currently available in the United States and Canada, with pending global regulatory approvals.
Solventum (NYSE: SOLV) reported its third quarter 2024 financial results, showing a 0.4% increase in sales to $2.082 billion and an organic sales increase of 0.3%. The company reported a GAAP EPS of $0.70 and an adjusted EPS of $1.64. Solventum generated $169 million in cash from operations and a free cash flow of $76 million. The company raised its full-year 2024 guidance, expecting organic sales growth in the upper half of 0% to 1%, adjusted EPS of $6.50 to $6.65, and free cash flow of $750 million to $850 million. Segment performance showed varied results, with MedSurg and Health Information Systems segments driving growth while Dental Solutions and Purification and Filtration segments declined. GAAP and adjusted operating income margins dropped due to lower gross margins and increased operating expenses.
Solventum (NYSE: SOLV) has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024 after the U.S. financial markets close. The company will also host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update.
Investors can access the conference call via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID #6342275. A replay of the webcast, along with the earnings press release, presentation slides, and supplemental financial disclosures, will be available on the Investor Relations section of the company's website.
Solventum (NYSE: SOLV), formerly 3M Health Care, has pledged to use 100% renewable electricity across its global operations by 2030. This commitment underscores the company's focus on sustainability and the healthcare industry's role in addressing climate change. Since 2021, Solventum has transitioned ten manufacturing sites to renewable electricity, accounting for 48% of its total electricity consumption. The company aims to increase this to 80% by 2025.
The transition is expected to result in a 45% reduction in scope 1 and 2 greenhouse gas emissions by 2030 from the 2021 baseline, equivalent to removing 20,000 cars from the road. CEO Bryan Hanson emphasized that this aligns with Solventum's mission of enabling better, smarter, safer healthcare, recognizing the direct impact of environmental health on human health.
Solventum (NYSE: SOLV) has appointed Dr. Ryan Egeland, MD, as its new Chief Medical Officer. Dr. Egeland will lead the Global Medical and Clinical Affairs team, focusing on enhancing the voice of clinicians and patients, fostering industry collaboration, and identifying innovation opportunities. He brings over 20 years of experience in research, surgery, and executive roles, most recently serving as CEO of Crossfire Medical.
Dr. Egeland's extensive background includes leadership positions at Cardiovascular Systems, Inc., Medtronic, Covidien, and ev3. He holds an M.D. from Harvard Medical School, a Ph.D. and M.B.A. from the University of Oxford as a Rhodes Scholar, and trained in plastic and reconstructive surgery at Northwestern Memorial Hospital. Solventum aims to leverage Dr. Egeland's expertise to advance its innovation pipeline and improve patient care globally.
FAQ
What is the current stock price of Solventum Corporation (SOLV)?
What is the market cap of Solventum Corporation (SOLV)?
